H.C. Wainwright lowered the firm’s price target on Cognition Therapeutics (CGTX) to $5 from $6 and keeps a Buy rating on the shares. The firm expects a “somewhat lengthened path” to market for zervimesine.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX: